EWA
ARTV

EverSource Wealth Advisors’s Artiva Biotherapeutics ARTV Stock Holding History

EverSource Wealth Advisors’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-159
Closed -$456 – 4483
2025
Q3 		$456 Buy
+159
New +$425 ﹤0.01% 3970

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCM
Revelation Capital Management Sausalito, California $67.4M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

EverSource Wealth Advisors's ARTV Position: Q4 2025 in Review

EverSource Wealth Advisors sold out of Artiva Biotherapeutics (ARTV) in Q4 2025, closing a stake of 159 shares — an estimated $456 sold.

EverSource Wealth Advisors first reported a position in ARTV in Q3 2025 and held it in 1 quarter. The position peaked at $456 in Q3 2025. 34 funds tracked by Wall St. Rank hold ARTV as of Q4 2025.

  • EverSource Wealth Advisors reported no remaining Artiva Biotherapeutics position as of Q4 2025 after selling out during the quarter.
  • EverSource Wealth Advisors sold 159 Artiva Biotherapeutics shares in Q4 2025, an estimated $456.
  • EverSource Wealth Advisors first reported a position in Artiva Biotherapeutics in Q3 2025 and held it in 1 quarter.
  • EverSource Wealth Advisors's Artiva Biotherapeutics position peaked at $456 in Q3 2025.
  • 34 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q4 2025.

Based on EverSource Wealth Advisors's 13F filing for Q4 2025, filed 6 Feb 2026.